Protease inhibitor levels in hair strongly predict virologie response to treatment

AIDS

Volumn 23, Issue 4, 2009, Pages 471-478

  Gandhi, Monica ^a   Ameli, Niloufar ^b   Bacchetti, Peter ^a   Gange, Stephen J ^c   Anastos, Kathryn ^d   Levine, Alexandra ^e,f   Hyman, Charles L ^g   Cohen, Mardge ^h   Young, Mary ⁱ   Huang, Yong ^b   Greenblatt, Ruth M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g SUNY Downstate Medical Center   (United States)

^h Georgetown University Medical Center ^*  (United States)

ⁱ GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiretroviral exposure; Atazanavir; Hair levels; Lopinavir; Protease inhibitors; Therapeutic drug monitoring; Virologic response; Women's interagency HIV study

Indexed keywords

ATAZANAVIR; LOPINAVIR PLUS RITONAVIR;

ADULT; AGE DISTRIBUTION; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DRUG HAIR LEVEL; FEMALE; HAIR ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RACE DIFFERENCE; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG MONITORING; EPIDEMIOLOGIC METHODS; FEMALE; HAIR; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MIDDLE AGED; OLIGOPEPTIDES; PATIENT COMPLIANCE; PYRIDINES; PYRIMIDINONES; RITONAVIR; SPECIMEN HANDLING; TREATMENT OUTCOME; VIRAL LOAD;

EID: 62349118443     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328325a4a9     Document Type: Article

References (46)

1. Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JS. Continued improvement in survival among HIV-infected individuals with newer forms of highly active anti-retroviral therapy. AIDS 2007; 21:685-692.
2. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr 2006; 43 (Suppl 1):S79-S87.
3. Back D, Khoo S, Gibbons S, Merry C. The role of therapeutic drug monitoring in treatment of HIV infection. Br J Clin Pharmacol 2001; 52:89S-96S.
4. Marzolini C, Buclin T, Decosterd L, Biollaz J, Telenti A. Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit 2001; 23:394-398.
5. Stahle L, Moberg L, Svensson J-O, Sonnerborg A. Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit 2004; 26:267-270.
6. Clevenbergh P, Boulme R, Kirstetter M, Dellamonica P. Efficacy, safety and predictive factors of virological success of a boosted amprenavir-based salvage regimen in heavily antiretroviral-experienced HIV-1-infected patients. HIV Med 2004; 5:284-288.
7. Clevenbergh P, Garaffo R, Durant J, Dellamonica P. Pharm-Adapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002; 16:2311-2315.
8. Wertheimer BZ, Freedberg KA, Walensky RP, Yazdanapah Y, Losina E. Therapeutic drug monitoring in HIV treatment: a literature review. HIV Clin Trials 2006; 7:59-69.
9. Demeter L, Jiang H, Mukherjee L, Morse G, DiFrancesco R, Klingman K, et al. A prospective, randomized, controlled, open-label trial evaluating the effect of therapeutic drug monitoring and protease inhibitor dose escalation on viral load responses in antiretroviral-experienced, HIV-infected patients with a normalized inhibitory quotient. In: 15th Conference on Retroviruses and Opportunistic Infections; 3-6 February 2008. Boston, MA.
10. Nettles RE, Kieffer TL, Parsons T, Johnson J, Cofrancesco J Jr, Gallant JE, et al. Marked intraindividual variability in anti-retroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006; 42:1189-1196.
11. Podsadecki T, Vrijens B, Touseet E, Rode R, Hanna G. White coat compliance patterns make therapeutic drug monitoring (TDM) a potentially unreliable tool for assessing long-term drug exposure. In: 13th Conference on Retroviruses and Opportunistic Infections; 5-8 February 2006. Denver, Colorado.
12. Pepin G, Gaillard Y. Concordance between self-reported drug use and findings in hair about cocaine and heroin. Forensic Sci Int 1997; 84:37-41.
13. Beumer JH, Bosman IJ, Maes RA. Hair as a biological specimen for therapeutic drug monitoring. Int J Clin Pract 2001; 55:353-357.
14. Nakahara Y. Hair analysis for abused and therapeutic drugs. J Chromatogr B Biomed Sci Appl 1999; 733:161-180.
15. Tsatsakis AM, Psillakis T, Paritsis N. Phenytoin concentration in head hair sections: a method to evaluate the history of drug use. J Clin Psychopharmacol 2000; 20:560-573.
16. Bernard L, Vuagnat A, Peytavin G, Hallouin MC, Bouhour D, Nguyen TH, et al. Relationship between levels of indinavir in hair and virologic response to highly active antiretroviral therapy. Ann Intern Med 2002; 137:656-659.
17. Bernard L, Peytavin G, Vuagnat A, de Truchis P, Perronne C. Indinavir concentrations in hair from patients receiving highly active antiretroviral therapy. Lancet 1998; 352:1757-1758.
18. Servais J, Peytavin G, Arendt V, Staub T, Schneider F, Hemmer R, et al. Indinavir hair concentration in highly active antiretroviral therapy-treated patients: association with viral load and drug resistance. AIDS 2001; 15:941-943.
19. Duval X, Peytavin G, Breton G, Ecobichon JL, Descamps D, Thabut G, Leport C. Hair versus plasma concentrations as indicator of indinavir exposure in HIV-1-infected patients treated with indinavir/ritonavir combination. AIDS 2007; 21:106-108.
20. Koenig RJ, Peterson CM, Jones RL, Saudek C, Lehrman M, Cerami A. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N Engl J Med 1976; 295:417-420.
21. Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin E, Messenkoff N. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair samples by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 2008; 22:3401-3409.
22. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The women's interagency HIV study. Epidemiology 1998; 9:117-125.
23. Bacon MC, von Wyl V, Alden C, Sharp G, Robison E, Hessol N, et al. The women's interagency HIV study: an observational cohort brings clinical sciences to the bench. Clin Diagn Lab Immunol 2005; 12:1013-1019.
24. Skopp G, Pötsch L, Mauden M. Stability of cannabinoids in hair samples exposed to sunlight. Clin Chem 2000; 46:1846-1848.
25. Cassani M, Da Re N, Giuliani L, Sesana F. Experience with hair testing in the clinical biochemistry laboratory of Ca' Granda Niguarda Hospital, Milan, Italy. Forensic Sci Int 1997; 84:17-24.
26. Kosuge K, Uematsu T, Araki SI, Matsuno H, Ohashi K, Nakashima M. Comparative dispositions of ofloxacin in human head, axillary, and pubic hairs. Antimicrob Agents Chemother 1998; 42:1298-1302.
27. Egge-Jacobsen W, Unger M, Niemann CU, Baluom M, Hirai S, Benet LZ, Christians U. Automated, fast, and sensitive quantification of drugs in human plasma by LC/LC-MS: quantification of 6 protease inhibitors and 3 nonnucleoside transcriptase inhibitors. Ther Drug Monit 2004; 26:546-562.
28. Villani P, Feroggio M, Gianelli L, Bartoli A, Montagna M, Maserati R, Regazzi MB. Antiretrovirals: simultaneous determination of five protease inhibitors and three nonnucleoside transcriptase inhibitors in human plasma by a rapid high-performance liquid chromatography: mass spectrometry assay. Ther Drug Monit 2001; 23:380-388.
29. Chi J, Jayewardene AL, Stone JA, Motoya T, Aweeka FT. Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC/MS/MS. J Pharm Biomed Anal 2002; 30:675-684.
30. Chi J, Jayewardene AL, Stone JA, Aweeka FT. An LC-MS-MS method for the determination of nevirapine, a nonnucleoside reverse transcriptase inhibitor, in human plasma. J Pharm Biomed Anal 2003; 31:953-959.
31. Frerichs VA, DiFrancesco R, Morse GD. Determination of protease inhibitors using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 787:393-403.
32. Department of Health and Human Services and Henry J. Kaiser Family Foundation living document. Guidelines for the use of antiretroviral agents in HIV-infected adolescents and adults. http://aidsinfo.nih.gov.
33. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004; 5:74-79.
34. Shapiro J. Clinical practice. Hair loss in women. N Engl J Med 2007; 357:1620-1630.
35. Centers for Disease Control and Prevention (CDC). HIV and AIDS in the United States: a picture of today's epidemic. http://www.cdc.gov/hiv/topics/ surveillance/united_states.htm.
36. Williams J, Patsalos PN, Mei Z, Schapel C, Wilson JF, Richens A. Relation between dosage of carbamazepine and concentration in hair and plasma samples from a compliant inpatient epileptic population. Ther Drug Monit 2001; 23:15-20.
37. Williams J, Patsalos P, Wilson J. Hair analysis as a potential index of therapeutic compliance in the treatment of epilepsy. Forensic Sci Int 1997; 84:113-122.
38. Shen M, Xiang P, Wu H, Shen B, Huang Z. Detection of antidepressant and antipsychotic drugs in human hair. Forensic Sci Int 2002; 126:153-161.
39. Thieme D, Sachs H. Examination of a long-term clozapine administration by high resolution segmental hair analysis. Forensic Sci Int 2007; 166:110-114.
40. Kronstrand R, Nystrom I, Josefsson M, Hodgins S. Segmental ion spray LC-MS-MS analysis of benzodiazepines in hair of psychiatric patients. J Anal Toxicol 2002; 26:479-484.
41. Cirimele V, Kintz P, Cosselin O, Ludes B. Clozapine dose-concentration relationships in plasma, hair and sweat specimens of schizophrenic patients. Forensic Sci Int 2000; 107:289-300.
42. Banh HL, Burton ME, Sperling MR. Interpatient and intrapatient variability in phenytoin protein binding. Ther Drug Monit 2002; 24:379-385.
43. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia 2002; 43 (Suppl 2):37-44.
44. Roustit M, Jlaiel M, Leclercq P, Stanke-Labesque F. Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women. Br J Clin Pharmacol 2008; 66:179-195.
45. Marcelin AG, Jarrousse B, Derache A, Ba M, Dakouo ML, Doumbia A, et al. HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen. AIDS 2007; 21:2341-2343.
46. Gandhi M, Bacchetti P, Ameli N, Huang Y, Greenblatt RM. Concentrations of lopinavir and ritonavir in hair are strongly correlated with virologic success [paper #51]. In: 14th Conference of Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, CA.